Early combination therapy for type 2 diabetes. Time for new decisions
نویسندگان
چکیده
منابع مشابه
Combination lipid therapy in type 2 diabetes.
To the Editor: In the Action to Control Car diovascular Risk in Diabetes (ACCORD) trial (ClinicalTrials.gov number, NCT00000620) report ed on by Ginsberg et al. (April 29 issue),1 the use of fenofibrate in patients with type 2 diabetes mellitus who were receiving simvastatin and who were at high risk for cardiovascular disease great ly reduced triglyceride levels but hardly increased levels ...
متن کامل[Early insulin therapy in type 2 diabetes?].
Type 2 diabetes is characterized by progressive decline in pancreatic beta cell function and persistent insulin resistance. Decreased beta cell mass and amyloid deposits in the islet are the pathological hallmark of the disease. Preserved beta cell function is the most important determinant of glucose disposal, even after adjustment for insulin sensitivity, which might modulate beta cell functi...
متن کاملa new approach to credibility premium for zero-inflated poisson models for panel data
هدف اصلی از این تحقیق به دست آوردن و مقایسه حق بیمه باورمندی در مدل های شمارشی گزارش نشده برای داده های طولی می باشد. در این تحقیق حق بیمه های پبش گویی بر اساس توابع ضرر مربع خطا و نمایی محاسبه شده و با هم مقایسه می شود. تمایل به گرفتن پاداش و جایزه یکی از دلایل مهم برای گزارش ندادن تصادفات می باشد و افراد برای استفاده از تخفیف اغلب از گزارش تصادفات با هزینه پائین خودداری می کنند، در این تحقیق ...
15 صفحه اولPractical combination therapy based on pathophysiology of type 2 diabetes
Type 2 diabetes is a complex, chronic, and progressive condition that often necessitates the use of multiple medications to achieve glycemic goals. Clinical guidelines generally recommend intensifying pharmacotherapy if glycemic goals are not achieved after 3 months of treatment. However, for many patients with type 2 diabetes, treatment intensification is delayed or does not occur. Initiating ...
متن کاملEffects of combination lipid therapy in type 2 diabetes mellitus.
BACKGROUND We investigated whether combination therapy with a statin plus a fibrate, as compared with statin monotherapy, would reduce the risk of cardiovascular disease in patients with type 2 diabetes mellitus who were at high risk for cardiovascular disease. METHODS We randomly assigned 5518 patients with type 2 diabetes who were being treated with open-label simvastatin to receive either ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medical Council
سال: 2019
ISSN: 2658-5790,2079-701X
DOI: 10.21518/2079-701x-2019-12-115-121